Summary of the Key Points
On September 7th, Makotian, a domestic medical device company founded by several former senior executives from Mindray Medical, officially listed on the Hong Kong Stock Exchange. On its first day of trading, the stock price fell below its issue price, closing at HK$8.8 from HK$15.42, with a total market value of HK$4.74 billion. Founded 15 years ago, the company started with self-developed infusion equipment and has since acquired several mature companies in various niche areas, establishing three main business segments: life support, minimally invasive interventional therapy, and in vitro diagnostics. Its products are sold in over 140 countries and cover 90% of the top-tier hospitals in China. Although revenue has been increasing year by year, profitability has been volatile. The company just turned from a loss in 2025 to a profit in the first quarter of this year, only to experience a slight loss again. Interestingly, despite the general trend of price cuts in national procurement auctions, its gross profit margin increased from 49.6% to 54.3%. The biggest question now is whether it can transform its scale advantage into a stable source of earnings after going public.
Detailed Explanation of the Key Points
1. A Strong Foundation from the "Medical Device Industry's Elite Training Ground"
The domestic medical device industry often refers to Mindray Medical as the "Elite Training Ground" because it has cultivated a large number of professionals who understand products, sales, and global operations. Makotian's core team is largely composed of former Mindray employees: two of the founders served as Mindray's COO and were in charge of global sales and strategy, while other key executives with over a decade of experience at Mindray managed research and development, supply chains, and domestic sales. Makotian started with a very practical approach, focusing on the "advanced infusion pumps" that are essential in hospital ICUs and operating rooms. These pumps can precisely control the rate and dosage of infusions and can even be operated remotely in strong magnetic fields (such as in MRI rooms or COVID-19 isolation wards), a technology that was previously largely dependent on imports. With this product, Makotian has dominated the domestic infusion workstation market for seven consecutive years, holding a 26% market share and becoming the first Chinese infusion pump brand to receive a four-star rating from a prestigious American medical device evaluation organization. This has helped the company build a customer base of more than 6,000 hospitals.
2. Accelerated Expansion through Acquisitions
Rather than developing everything from scratch over decades, Makotian used acquisitions to quickly expand into different medical device areas. For example, it spent HK$1.7 billion to acquire Weidekang, a company specializing in digestive endoscope consumables, instantly entering the top three in the domestic market for these products. It also acquired Penlon, a well-established British manufacturer of anesthetic equipment, which addressed its lack of anesthetic machines and vaporizers. Additionally, it bought established European distributors, allowing it to establish overseas sales networks without starting from scratch. This strategy enabled Makotian to grow from a single infusion device manufacturer into a comprehensive medical device company with over 300 products in just three years. However, this approach came with a significant cost in the form of goodwill of HK$928 million, which could become a hidden performance risk if the acquired companies fail to meet expectations.
3. Surprising Increase in Gross Profit Margin Despite Price Cuts
It may seem strange that Makotian's gross profit margin increased from less than 50% to 54.3% despite national procurement auctions requiring price cuts of 30%-70%. The reason is simple: nearly half of its revenue now comes from high-profit margin minimally invasive interventional consumables, which have not yet been affected by the price cuts. Moreover, the company has increased production capacity to over 90%, reducing the cost per unit. Its infusion equipment, which accounts for only 0.3% of its revenue, has not been significantly impacted by the price cuts. Another factor is that nearly half of its revenue comes from overseas markets, where there are no such price cuts, resulting in higher prices. However, this positive trend also highlights concerns about the company's profitability, as its profit base is still fragile. The loss in the first quarter of 2026 was mainly due to expenses related to employee stock options and listing-related costs, indicating that its profit margins are not yet solid. Additionally, 14% of its revenue comes from contract manufacturing for overseas brands, and its own global brand has not yet taken off. The company is also facing the loss of thousands of domestic distributors and slower payment collection, raising doubts about its ability to maintain high profit margins in the long term.
4. Initial Stock Price Drop as a Sign of Market Skepticism
The initial stock price drop after the listing does not necessarily indicate poor company quality. It reflects the pragmatic attitude of Hong Kong's medical device investors, who want to see tangible evidence of sustained profitability. The current market value of HK$4.74 billion is a bet on the company's ability to leverage its three key strengths:
- Equipment and Consumables: Makotian sells equipment and provides the accompanying consumables, creating a self-sustaining revenue stream. For example, by selling thromboelasticity detectors at low prices, the company can generate recurring revenue from the consumables sold alongside the equipment.
- Globalization: With offices in 10 countries and acquired overseas factories and channels, Makotian can target emerging markets with higher profit margins.
- Integrated Solutions: The company is moving from selling individual products to providing comprehensive software and hardware solutions for hospitals, offering higher margins.
Makotian has successfully grown from scratch over the past 15 years, but the key to its success will be its ability to integrate the acquired businesses and convert its scale advantage into stable profits, enabling it to join the top ranks of the domestic medical device industry.